NIKKEI 225
39,667.07 +493.92 (+1.26%) HANG SENG
18,139.98 +67.08 (+0.37%) CRUDE OIL
81.35 +0.52 (+0.64%) GOLD FUTURES
2,327.60 -3.20 (-0.14%) DOW
39,112.16 -299.05 (-0.76%) Bitcoin GBP
48,536.14 +359.27 (+0.75%)
DYN Dec 2024 40.000 call
| Previous close | 4.8000 |
| Open | 4.8000 |
| Bid | 3.1000 |
| Ask | 4.5000 |
| Strike | 40.00 |
| Expiry date | 2024-12-20 |
| Day's range | 4.8000 - 4.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 23 |
GlobeNewswireDyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central nervous system (CNS). The data were presented at the New D
- GlobeNewswire
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today highlighted new preclinical data for DYNE-302, its product candidate for facioscapulohumeral muscular dystroph
- GlobeNewswire
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne’s w
